LSI Alumni Funding Report May 2025

May was another impressive month of funding for the LSI Alumni, raising over $120 million in new capital across 13 new deals. Our monthly Alumni Funding Update features transactions made by these medical device startups and their investors, as well as links to our proprietary media and coverage of the companies themselves.

Companies featured in the May 2025 update include: 

Accelus

Obtained new growth funding led by Concord Health Partners to drive commercial scaling and advance the development of its expandable spinal implant portfolio. The company also named seasoned medtech executive Bernie Haffey as Chairman of the Board to help steer its next stage of strategic expansion.

Cosm Medical

Completed the initial tranche of its Seed Extension round to fast-track commercialization of its personalized, AI-enabled 3D-printed pelvic health solutions. The funding will support post-FDA clearance growth and upcoming clinical presentations at IUGA and other major U.S. women’s health conferences.

EBR Systems

Announced a fully underwritten institutional placement to raise $36.1M in support of commercializing its WiSE CRT system—the only FDA-approved wireless cardiac pacing device for heart failure. The funding will enable a limited market launch in 2025 and scale U.S. distribution in 2026.

Hy2Care

Raised €4.5M to support U.S. clinical trial readiness and advance global expansion efforts for CartReviveⓇ, a minimally invasive hydrogel implant designed for cartilage repair. With backing from the European Innovation Council Fund and strategic investors like Brightlands Venture Partners, the funding will help accelerate post-FDA IDE preparations and pave the way for commercial entry in Europe and other markets.

INBRAIN Neuroelectronics

Received a €4M grant through Spain’s PERTE Chip initiative to fast-track the development of its graphene-based brain-computer interface technology. The support reinforces INBRAIN’s goal to deliver highly precise neuromodulation treatments for neurological conditions and strengthen Spain’s role in deep tech innovation.

Insight Surgery

Raised $2.5M in Series A funding to expand nationwide adoption of its FDA-cleared, patient-specific surgical guide platform. With support from Nodenza Venture Partners, the company plans to scale manufacturing, grow its U.S. workforce, and explore AI enhancements to improve surgical outcomes in orthopedics and other specialties.

Lenoss Medical

Closed an oversubscribed $1M bridge round, bringing in $2.2M to fast-track the commercialization of its OsteoPearl™ implant for treating vertebral compression fractures. The company also marked its 200th surgical case with the allograft implant, highlighting strong clinical uptake and increasing market traction.

OncoHost

Received a €2.5M Horizon Europe grant in collaboration with Heidelberg University Hospital, European Institute of Oncology, and Virgen Macarena University Hospital to advance precision oncology in immunotherapy-treated patients. OncoHost is working to develop an innovative biomarker that can predict treatment response across five cancer types.

Orixha

Was awarded €4M in co-financing through France 2030’s “First Factory” initiative to establish an industrial-scale reprocessing facility for its Liquid2Breathe (L2B) fluid, used in the Vent2Cool liquid ventilation system. Scheduled to open in 2028, the plant will support high-volume production and reprocessing of respiratory fluid.

Prana Surgical

Received a $900K supplemental grant from the Cancer Prevention and Research Institute of Texas (CPRIT) to support clinical validation of its minimally invasive, image-guided Prana System for lung cancer. The funding will help drive product development, grow the team, and advance innovation initiatives within Texas.

Pulnovo Medical

Secured new funding from EQT following CE-MDR certification of its PADN-based pulmonary hypertension treatment system, with continued support from Qiming Venture Partners. The investment will help drive Pulnovo Medical’s global growth through clinical development, regulatory milestones, and commercial rollout.

QV Bioelectronics

Received £1.2M in funding from Innovate UK’s Biomedical Catalyst to progress GRACE, an implantable therapy designed for patients with brain tumors. The grant will fund essential preclinical work as QV prepares to launch its first-in-human trial for this innovative approach.

Salvia BioElectronics

Raised $60M in Series B funding, led by Innovation Industries, to finalize clinical development and gear up for the commercial launch of MySalvia Therapy, a novel neuromodulation solution for chronic migraine. The investment will support regulatory progress across the U.S., Europe, and Australia, furthering Salvia’s mission to improve outcomes for people affected by chronic migraine.

More News

Stay tuned for more updates as these medical technology companies continue to innovate and lead the way in the medtech industry. As we approach LSI Asia ‘25 in Singapore, these achievements remind us of the incredible progress being made in the medtech sector.

LSI-Alumni-funding-activity-in-May-2025-including-emerging-medtech-companies-Hy2Care-and-Insight-Surgery
Free Download
The Complete LSI Alumni Funding Report
Get the complete spreadsheet, which includes these 13 new deals from medical technology companies in May of 2025, totaling over $120 million from the 2025 LSI Alumni Funding Report.
lsi logo

Events

Explore Media

Market Intelligence

Resources

Market Intelligence

Schedule an exploratory call

Request Info

17011 Beach Blvd, Suite 500 Huntington Beach, CA 92647

714-847-3540

© 2025 Life Science Intelligence, Inc., All Rights Reserved. | Privacy Policy